Modulation of chemotherapeutic efficacy by vascular disrupting agents: Optimizing the sequence and schedule

Journal of Clinical Oncology

Volumn 30, Issue 7, 2012, Pages 760-761

  Wang, Eunice S ^a   Pili, Roberto ^a   Seshadri, Mukund ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; COMBRETASTATIN; PACLITAXEL; VADIMEZAN;

ADVANCED CANCER; BLOOD FLOW; CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIOVASCULAR FUNCTION; CIRCULATING TUMOR CELL; CONTRAST ENHANCEMENT; DRUG EFFICACY; DRUG PENETRATION; ENDOTHELIAL PROGENITOR CELL; HUMAN; HYPOXIA; LETTER; LUNG NON SMALL CELL CANCER; MICROTUBULE; MODULATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROCESS OPTIMIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DATA INTERPRETATION, STATISTICAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MOLECULAR TARGETED THERAPY; NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XANTHONES;

EID: 84857542001     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.39.3934     Document Type: Letter

References (15)

1. Lara PN Jr, Douillard JY, Nakagawa K, et al: Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol 29:2965-2971, 2011
2. Lorusso PM, Boerner SA, Hunsberger S: Clinical development of vascular disrupting agents: What lessons can we learn from ASA404? J Clin Oncol 29:2952-2955, 2011
3. Baguley BC, Siemann DW: Temporal aspects of the action of ASA404 (Vadimezan; DMXAA). Expert Opin Investig Drugs 19:1412-1425, 2010
4. Siemann DW, Mercer E, Lepler S, et al: Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 99:1-6, 2002 (Pubitemid 34273190)
5. Martinelli M, Bonezzi K, Riccardi E, et al: Sequence dependent antitumor efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel. Br J Cancer 97:888-894, 2007 (Pubitemid 47519312)
6. Seshadri M, Spernyak JA, Mazurchuk R, et al: Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: Implications for combination therapy. Clin Cancer Res 11:4241-4250, 2005 (Pubitemid 40791591)
7. Seshadri M, Ciesielski MJ: MRI-based characterization of vascular disruption by 5,6-dimethylxanthenone-4-acetic acid in gliomas. J Cereb Blood Flow Metab 29:1373-1382, 2009
8. Zhao L, Ching L-M, Kestell P, et al: Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid: Increased tumor vascular permeability. Int J Cancer 116:322-326, 2005 (Pubitemid 40967272)
9. Shaked Y, Ciarrocchi A, Franco M, et al: Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313:1785-1787, 2006 (Pubitemid 44454154)
10. Siemann DW, Shi W: Efficacy of combined antiangiogenic and vascular disrupting agents in solid tumors. Int J Rad Oncol 60:1233-1240, 2004 (Pubitemid 39440810)
11. Wang H, Li J, Chen F, et al: Morphological, functional and metabolic imaging biomarkers: Assessment of vascular-disrupting effect on rodent liver tumours. Eur Radiol 20:2013-2026, 2010
12. Galbraith SM, Rustin GJ, Lodge MA, et al: Effects of 5,6- dimethylxanthenone-4- acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 20:3826-3840, 2002
13. Galbraith SM, Maxwell RJ, Lodge MA, et al: Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 21:2831-2842, 2003 (Pubitemid 46621830)
14. Zweifel M, Padhani AR: Perfusion MRI in the early clinical development of antivascular drugs: Decorations or decision making tools? Eur J Nucl Med Mol Imaging 37:S164-S182, 2010
15. The Quotations Page: Quotations by Author Eleanor Roosevelt (1884- 1962). http://www.quotationspage.com/quotes/Eleanor-Roosevelt